Computational Assessment and Pharmacological Property Breakdown of Eight Patented and Candidate Drugs against Four Intended Targets in Alzheimer’s Disease — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Computational Assessment and Pharmacological Property Breakdown of Eight Patented and Candidate Drugs against Four Intended Targets in Alzheimer’s Disease
Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Jahangirnagar University, Savar, Dhaka, Bangladesh
,
Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Jahangirnagar University, Savar, Dhaka, Bangladesh
,
Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Jahangirnagar University, Savar, Dhaka, Bangladesh
,
Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Jahangirnagar University, Savar, Dhaka, Bangladesh
,
Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Jahangirnagar University, Savar, Dhaka, Bangladesh
,
Department of Genetic Engineering and Biotechnology, Faculty of Life Sciences, Shahjahal University of Science and Technology, Sylhet, Bangladesh
,
Department of Microbiology, School of Life Sciences, Independent University Bangladesh, Dhaka, Bangladesh
1 Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Jahangirnagar University, Savar, Dhaka, Bangladesh
2 Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Jahangirnagar University, Savar, Dhaka, Bangladesh
3 Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Jahangirnagar University, Savar, Dhaka, Bangladesh
4 Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Jahangirnagar University, Savar, Dhaka, Bangladesh
5 Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Jahangirnagar University, Savar, Dhaka, Bangladesh
6 Department of Genetic Engineering and Biotechnology, Faculty of Life Sciences, Shahjahal University of Science and Technology, Sylhet, Bangladesh
7 Department of Microbiology, School of Life Sciences, Independent University Bangladesh, Dhaka, Bangladesh
Alzheimer’s Disease (AD) is the most prevalent age-related dementia. AD can be caused by abnormal processing of amyloid precursor protein (APP) or by oxidative stress or may be due to the actions of kinases or the degeneration and loss of functions of neurons in the brain. Although various treatments have already gained success in the in vitro studies, however, till now not a single satisfactory drug has been proven that can cure this disease permanently till now . In this study, the best possible drug has been determined from a group of drug molecules using methods of molecular docking. Molecular docking is a computational approach which helps to determine the best molecule from a group of molecules which may bind with the highest affinity with the intended target by mimicking the original biological environment in a computer. The tested drug molecules in this experiment are the disease modifying agents, capable of inhibiting a particular protein involving in the AD pathway. Eight drug molecules (ligands)- memantine ( -4.075 Kcal/mol) , hymenialdisine ( -8.079 Kcal/mol) , tideglusib ( -6.445 Kcal/mol) , kenpaullone ( - 7.545 Kcal/mol), dihydrospiro[dibenzo[a,d][7]annulene-5,4 ’ -imidazol] (-4.742 Kcal/mol), harmine (-7.57 Kcal/mol), harmol (-6.583 Kcal/mol) and 1-Methyl-4-Phenylpyridinium (-5.214 Kcal/mol), have been docked success fully against four targets (proteins)-N-Methyl-D-Aspartate Receptor (NMDAR), glycogen synthase kinase-3 β (GSK-3 β ), beta-secretase ( β -secretase) and dual specificity tyrosine (Y)-phosphorylation-regulated kinase 1A (DYR-K1A) in this experiment which are intended targets in current AD treatment approaches. Investigation of docking results, druglikeness properties and ADME/T testing results suggest that the best findings of this experiment are memantine, hymenialdisine, dihydrospiro[dibenzo[a,d][7]annulene-5,4 ’ -imi- dazol] and harmol, that could be the best possible drugs for the treatment of AD.
Suh, W.H., Suslick, K.S. and Suh, Y.H. (2005) Therapeutic Agents for Alzheimer’s Disease. Current Medicinal Chemistry-Central Nervous System Agents, 5, 259-269. https://doi.org/10.2174/156801505774913035
Ferri, C.P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., et al. (2005) Global Prevalence of Dementia: A Delphi Consensus Study. The Lancet, 366, 2112-2117. https://doi.org/10.1016/S0140-6736(05)67889-0
Merriam, A.E., Aronson, M.K., Gaston, P., Wey, S.L. and Katz, I. (1988) The Psychiatric Symptoms of Alzheimer’s Disease. Journal of the American Geriatrics Society, 36, 7-22. https://doi.org/10.1111/j.1532-5415.1988.tb03427.x
Nordberg, A. and Svensson, A.L. (1998) Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease. Drug Safety, 19, 465-480. https://doi.org/10.2165/00002018-199819060-00004
Hardy, J.A. and Higgins, G.A. (1992) Alzheimer’s Disease: The Amyloid Cascade Hypothesis. Science, 256, 184-186. https://doi.org/10.1126/science.1566067
Markesbery, W.R. (1997) Oxidative Stress Hypothesis in Alzheimer’s Disease. Free Radical Biology and Medicine, 23, 134-147. https://doi.org/10.1016/S0891-5849(96)00629-6
Francis, P.T., Palmer, A.M., Snape, M. and Wilcock, G.K. (1999) The Cholinergic Hypothesis of Alzheimer’s Disease: A Review of Progress. Journal of Neurology, Neurosurgery & Psychiatry, 66, 137-147. https://doi.org/10.1136/jnnp.66.2.137
Galimberti, D. and Scarpini, E. (2011) Disease-Modifying Treatments for Alzheimer’s Disease. Therapeutic Advances in Neurological Disorders, 4, 203-216. https://doi.org/10.1177/1756285611404470
Danysz, W. and Parsons, C.G. (2003) The NMDA Receptor Antagonist Memantine as a Symptomatological and Neuroprotective Treatment for Alzheimer’s Disease: Preclinical Evidence. International Journal of Geriatric Psychiatry, 18, S23-S32. https://doi.org/10.1002/gps.938
Martinez, A., Castro, A., Dorronsoro, I. and Alonso, M. (2002) Glycogen Synthase Kinase 3 (GSK-3) Inhibitors as New Promising Drugs for Diabetes, Neurodegeneration, Cancer, and Inflammation. Medicinal Research Reviews, 22, 373-384. https://doi.org/10.1002/med.10011
del Ser, T., Steinwachs, K.C., Gertz, H.J., Andres, M.V., Gomez-Carrillo, B., Medina, M., et al. (2013) Treatment of Alzheimer’s Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study. Journal of Alzheimer’s Disease, 33, 205-215. https://doi.org/10.3233/JAD-2012-120805
Leost, M., Schultz, C., Link, A., Wu, Y.Z., Biernat, J., Mandelkow, E.M., Bibb, J.A., Snyder, G.L., Greengard, P., Zaharevitz, D.W. and Gussio, R. (2000) Paullones Are Potent Inhibitors of Glycogen Synthase Kinase-3β and Cyclin-Dependent Kinase 5/p25. European Journal of Biochemistry, 267, 5983-5994. https://doi.org/10.1046/j.1432-1327.2000.01673.x
Quagliato, D.A., Andrae, P.M., Fan, Y. and Wyeth, L.L.C. (2009) Dihydrospiro [Dibenzo[a, d][7]Annulene-5,4’-imidazol] Compounds for the Inhibition of Beta-Secretase. U.S. Patent No. 7582667. https://doi.org/10.2210/pdb4dus/pdb
Smith, B., Medda, F., Gokhale, V., Dunckley, T. and Hulme, C. (2012) Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer’s? ACS Chemical Neuroscience, 3, 857-872. https://doi.org/10.1021/cn300094k
Riedel, G., Platt, B. and Micheau, J. (2003) Glutamate Receptor Function in Learning and Memory. Behavioural Brain Research, 140, 1-47. https://doi.org/10.1016/S0166-4328(02)00272-3
Collingridge, G.L., Olsen, R.W., Peters, J. and Spedding, M. (2009) A Nomenclature for Ligand-Gated Ion Channels. Neuropharmacology, 56, 2-5. https://doi.org/10.1016/j.neuropharm.2008.06.063
Wang, R. and Reddy, P.H. (2017) Role of Glutamate and NMDA Receptors in Alzheimer’s Disease. Journal of Alzheimer’s Disease, 57, 1041-1048. https://doi.org/10.3233/JAD-160763
Choi, D.W. (1988) Glutamate Neurotoxicity and Diseases of the Nervous System. Neuron, 1, 623-634. https://doi.org/10.1016/0896-6273(88)90162-6
Talantova, M., Sanz-Blasco, S., Zhang, X., Xia, P., Akhtar, M.W., Okamoto, S.I., et al. (2013) Aβ Induces Astrocytic Glutamate Release, Extrasynaptic NMDA Receptor Activation, and Synaptic Loss. Proceedings of the National Academy of Sciences, 110, E2518-E2527. https://doi.org/10.1073/pnas.1511280112
De Felice, F.G., Velasco, P.T., Lambert, M.P., Viola, K., Fernandez, S.J., Ferreira, S.T., et al. (2007) Aβ Oligomers Induce Neuronal Oxidative Stress through an N-methyl-D-aspartate Receptor-Dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine. Journal of Biological Chemistry, 282, 11590-11601. https://doi.org/10.1074/jbc.M607483200
Vance, K.M., Simorowski, N., Traynelis, S.F. and Furukawa, H. (2011) Ligand-Specific Deactivation Time Course of GluN1/GluN2D NMDA Receptors. Nature Communications, 2, Article No. 294. https://doi.org/10.1038/ncomms1295
Plattner, F., Angelo, M. and Giese, K.P. (2006) The Roles of Cyclin-Dependent Kinase 5 and Glycogen Synthase Kinase 3 in Tau Hyperphosphorylation. Journal of Biological Chemistry, 281, 25457-25465. https://doi.org/10.1074/jbc.M603469200
Mattson, M.P. (2004) Pathways towards and Away from Alzheimer’s Disease. Nature, 430, 631-639. https://doi.org/10.1038/nature02621
Hardy, J. and Selkoe, D.J. (2002) The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics. Science, 297, 353-356. https://doi.org/10.1126/science.1072994
Roberds, S.L., Anderson, J., Basi, G., Bienkowski, M.J., Branstetter, D.G., Chen, K.S., et al. (2001) BACE Knockout Mice Are Healthy Despite Lacking the Primary β-Secretase Activity in Brain: Implications for Alzheimer’s Disease Therapeutics. Human Molecular Genetics, 10, 1317-1324. https://doi.org/10.1093/hmg/10.12.1317
Kojro, E. and Fahrenholz, F. (2005) The Non-Amyloidogenic Pathway: Structure and Function of α-Secretases. Sub-Cellular Biochemistry, 38, 105-127. https://doi.org/10.1007/0-387-23226-5_5
Reddy, P.H. and Beal, M.F. (2008) Amyloid Beta, Mitochondrial Dysfunction and Synaptic Damage: Implications for Cognitive Decline in Aging and Alzheimer’s Disease. Trends in Molecular Medicine, 14, 45-53. https://doi.org/10.1016/j.molmed.2007.12.002
Augustinack, J.C., Schneider, A., Mandelkow, E.M. and Hyman, B.T. (2002) Specific Tau Phosphorylation Sites Correlate with Severity of Neuronal Cytopathology in Alzheimer’s Disease. Acta Neuropathologica, 103, 26-35. https://doi.org/10.1007/s004010100423
Eldar-Finkelman, H. (2002) Glycogen Synthase Kinase 3: An Emerging Therapeutic Target. Trends in Molecular Medicine, 8, 126-132. https://doi.org/10.1016/S1471-4914(01)02266-3
Hanger, D.P., Byers, H.L., Wray, S., Leung, K.Y., Saxton, M.J., Seereeram, A., et al. (2007) Novel Phosphorylation Sites in Tau from Alzheimer Brain Support a Role for Casein Kinase 1 in Disease Pathogenesis. Journal of Biological Chemistry, 282, 23645-23654. https://doi.org/10.1074/jbc.M703269200
Otth, C., Concha, I.I., Arendt, T., Stieler, J., Schliebs, R., González-Billault, C. and Maccioni, R.B. (2002) AβPP Induces cdk5-Dependent Tau Hyperphosphorylation in Transgenic Mice Tg2576. Journal of Alzheimer’s Disease, 4, 417-430. https://doi.org/10.3233/JAD-2002-4508
Llorens-Marítin, M., Jurado, J., Hernández, F. and ávila, J. (2014) GSK-3β, a Pivotal Kinase in Alzheimer Disease. Frontiers in Molecular Neuroscience, 7, 46. https://doi.org/10.3389/fnmol.2014.00046
Sarojini, B.K., Vidyagayatri, M., Darshanraj, C.G., Bharath, B.R. and Manjunatha, H. (2010) DPPH Scavenging Assay of Novel 1, 3-disubstituted-1H-pyrazol-5-ols and Their in Silico Studies on Some Proteins Involved in Alzheimer’s Disease Signaling Cascade. Letters in Drug Design & Discovery, 7, 214-224. https://doi.org/10.2174/157018010790596588
Li, R., Lindholm, K., Yang, L.B., Yue, X., Citron, M., Yan, R., et al. (2004) Amyloid β Peptide Load Is Correlated with Increased β-Secretase Activity in Sporadic Alzheimer’s Disease Patients. Proceedings of the National Academy of Sciences, 101, 3632-3637. https://doi.org/10.1073/pnas.0205689101
LaFerla, F.M., Green, K.N. and Oddo, S. (2007) Intracellular Amyloid-β in Alzheimer’s Disease. Nature Reviews Neuroscience, 8, 499-509. https://doi.org/10.1038/nrn2168
Yan, R. and Vassar, R. (2014) Targeting the β Secretase BACE1 for Alzheimer’s Disease Therapy. The Lancet Neurology, 13, 319-329. https://doi.org/10.1016/S1474-4422(13)70276-X
Bramblett, G.T., Goedert, M., Jakes, R., Merrick, S.E., Trojanowski, J.Q. and Lee, V.M. (1993) Abnormal Tau Phosphorylation at Ser396 in Alzheimer’s Disease Recapitulates Development and Contributes to Reduced Microtubule Binding. Neuron, 10, 1089-1099. https://doi.org/10.1016/0896-6273(93)90057-X
Ryoo, S.R., Jeong, H.K., Radnaabazar, C., Yoo, J.J., Cho, H.J., Lee, H.W., Kim, I.S., et al. (2007) DYRK1A-Mediated Hyperphosphorylation of Tau A Functional Link between Down Syndrome and Alzheimer Disease. Journal of Biological Chemistry, 282, 34850-34857. https://doi.org/10.1074/jbc.M707358200
Kolb, P. and Irwin, J.J. (2009) Docking Screens: Right for the Right Reasons? Current Topics in Medicinal Chemistry, 9, 755-770. https://doi.org/10.2174/156802609789207091
Levine, D., Facello, M., Hallstrom, P., Reeder, G., Walenz, B. and Stevens, F. (1997) Stalk: An Interactive System for Virtual Molecular Docking. IEEE Computational Science and Engineering, 4, 55-65. https://doi.org/10.1109/99.609834
Selick, H.E., Beresford, A.P. and Tarbit, M.H. (2002) The Emerging Importance of Predictive ADME Simulation in Drug Discovery. Drug Discovery Today, 7, 109-116. https://doi.org/10.1016/S1359-6446(01)02100-6
Li, A.P. (2001) Screening for Human ADME/Tox Drug Properties in Drug Discovery. Drug Discovery Today, 6, 357-366. https://doi.org/10.1016/S1359-6446(01)01712-3
(2015) Schrodinger Release 2015-1: Maestro. Schrodinger, LLC, New York. https://www.schrodinger.com/maestro
Visualizer, D.S. (2017) Release 4.1. Accelrys Inc., San Diego. https://www.3dsbiovia.com
Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J. (1997) Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Advanced Drug Delivery Reviews, 23, 3-25. https://doi.org/10.1016/S0169-409X(96)00423-1
Lipinski, C.A. (2004) Lead- and Drug-Like Compounds: The Rule-of-Five Revolution. Drug Discovery Today: Technologies, 1, 337-341. https://doi.org/10.1016/j.ddtec.2004.11.007
Yuriev, E. and Ramsland, P.A. (2013) Latest Developments in Molecular Docking: 2010-2011 in Review. Journal of Molecular Recognition, 26, 215-239. https://doi.org/10.1002/jmr.2266
Hubbard, R.E. and Kamran Haider, M. (2001) Hydrogen Bonds in Proteins: Role and Strength. https://doi.org/10.1002/9780470015902.a0003011.pub2
Sander, T. (2001) OSIRIS Property Explorer. Organic Chemistry Portal. https://www.organic-chemistry.org/prog/peo
Pollastri, M.P. (2010) Overview on the Rule of Five. Current Protocols in Pharmacology, 49, 9-12. https://doi.org/10.1002/0471141755.ph0912s49
Guengerich, F.P. (1999) Cytochrome P-450 3A4: Regulation and Role in Drug Metabolism. Annual Review of Pharmacology and Toxicology, 39, 1-7. https://doi.org/10.1146/annurev.pharmtox.39.1.1
Ghose, A.K., Viswanadhan, V.N. and Wendoloski, J.J. (1999) A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug Databases. Journal of Combinatorial Chemistry, 1, 55-68. https://doi.org/10.1021/cc9800071
Veber, D.F., Johnson, S.R., Cheng, H.Y., Smith, B.R., Ward, K.W. and Kopple, K.D. (2002) Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. Journal of Medicinal Chemistry, 45, 2615-2623. https://doi.org/10.1021/jm020017n
Egan, W.J., Merz, K.M. and Baldwin, J.J. (2000) Prediction of Drug Absorption Using Multivariate Statistics. Journal of Medicinal Chemistry, 43, 3867-3877. https://doi.org/10.1021/jm000292e
Muegge, I., Heald, S.L. and Brittelli, D. (2001) Simple Selection Criteria for Drug-Like Chemical Matter. Journal of Medicinal Chemistry, 44, 1841-1846. https://doi.org/10.1021/jm015507e
Ertl, P. and Schuffenhauer, A. (2009) Estimation of Synthetic Accessibility Score of Drug-Like Molecules Based on Molecular Complexity and Fragment Contributions. Journal of Cheminformatics, 1, Article No. 8. https://doi.org/10.1186/1758-2946-1-8
Martin, Y.C. (2005) A Bioavailability Score. Journal of Medicinal Chemistry, 48, 3164-3170. https://doi.org/10.1021/jm0492002